Pancreatic Cancer Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Pancreatic Cancer Market is Segmented By Treatment Type (Targeted Therapies, Chemotherapy, Surgery, Other Treatments), By End-user (Hospitals, Specialty Clinics, Home care, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Pancreatic Cancer Market Size

Global Pancreatic Cancer Market reached US$ 2.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 5.7 billion by 2030. The global Pancreatic Cancer market is expected to exhibit a CAGR of 11.1% during the forecast period (2024-2031).

Chemotherapy medications are used to kill or stop cancer cell division. Adjuvant chemotherapy is administered after surgery to eradicate any cancer cells left over, neoadjuvant chemotherapy is administered prior to surgery to reduce the tumor, and primary treatment for advanced or metastatic pancreatic cancer.

Market Summary

To Know More Insights - Download Sample

Market Dynamics

Increasing Prevalence of Pancreatic Cancer is Driving the Global Pancreatic Cancer Market Growth

Pancreatic cancer cases are increasing. Prior to implementing policies and interventions, it is critical to comprehend patterns in pancreatic cancer. Pancreatic cancer has a higher incidence, prevalence, and death in nations with high human development indices (HDI). The fourth greatest cause of cancer fatalities is pancreatic cancer, which is the tenth most prevalent cancer in men and the eighth most common in women.

The incidence of pancreatic cancer has increased as a result of obesity, passive smoking, and chronic inflammation. The risk of pancreatic cancer is influenced by what we eat and drink by 30% to 50%. As life expectancy rises along with a rising HDI, pancreatic cancer incidence is increasing in the Asia-Pacific region. Pancreatic cancer is underreported in underdeveloped nations in the Asia-Pacific area due to poor cancer registries.

FDA Approval for Products is Driving the Global Pancreatic Cancer Market Growth

For instance, in January 2022, the United States Food and Drug Administration (FDA) granted Orphan Drug designation to MT-601, a multi-tumor-associated antigen (MultiTAA)-specific T cell product optimized for the treatment of hematological malignancies and solid tumor indications produced by Marker Therapeutics, Inc., a clinical-stage immuno-oncology company.

Side Effects Associated with Therapeutics are Hampering the Global Pancreatic Cancer Market Growth

Therapeutics for pancreatic cancer can have a variety of side effects, which might differ depending on the exact treatment method and unique patient variables. Chemotherapy can cause vomiting and nauseous, feeble and weary, loss of hair decrease in appetite, constipation or diarrhea, mouth ulcers greater chance of infection, blood conditions (such as anemia and a low platelet count), perivascular neuropathy, which causes tingling or numbness in the hands or feet, depending on the chemotherapy medicines used, kidney or liver issues.

Market Segment Analysis

The global pancreatic cancer market is segmented based on type, end-user, and region.

Chemotherapy Segment is Expected to Hold A Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 37.6% of the pancreatic cancer market in 2022. Chemotherapy is typically most successful when two or more medications are administered concurrently (particularly as adjuvant or neoadjuvant therapy). A single medication (often gemcitabine, 5-FU, or capecitabine) may be administered for patients who are not healthy enough for combination therapies.

Gemcitabine, 5-fluorouracil (5-FU), Oxaliplatin, Albumin-bound Paclitaxel (Abraxane), Capecitabine (an oral 5-FU medicine), Cisplatin, and Irinotecan are the most popular medications used for both adjuvant and neoadjuvant chemotherapy.

Source: DataM Intelligence Analysis (2023)

Market Geographical Share

North Americba Holds a Dominant Position in the Global Pancreatic Cancer Market

North America is estimated to hold around 39.3% of the total market share throughout the forecast period. Rising pancreatic cancer and advancements in treatment and diagnosis boost regional growth over the forecast period. Estimates for pancreatic cancer in the United States for 2023 from the American Cancer Society state that a total of 64,050 individuals will receive a pancreatic cancer diagnosis (33,130 males and 30,920 women).

In total, 50,550 people will succumb to pancreatic cancer (26,620 males and 23,930 women). About 3% of cancer cases and 7% of cancer-related fatalities in the US are caused by pancreatic cancer.

Source: DataM Intelligence Analysis (2023)

Pancreatic Cancer Market Companies

The major global players in the market include Myriad Genetics Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Viatris Inc., Boston Scientific Corporation, Clovis Oncology, and GlaxoSmithKline among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war affected the pancreatic cancer market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. People, including patients and medical personnel, displaced as a result of the violence. Displacement interfere with continuity of care, making it difficult for patients with pancreatic cancer to get timely and effective treatment.

Additionally, the delivery of care is impacted by the need for healthcare personnel to leave the area or by their having to work in challenging circumstances.

Artificial Intelligence Analysis

Artificial intelligence (AI) is increasingly being used in the pancreatic cancer market to improve various aspects of the customer experience. The goal of ongoing research and development is to find new treatment targets, investigate combination medicines, and advance early detection and diagnosis techniques. The market is anticipated to grow as a result of investments made in pancreatic cancer research and development initiatives.

By Treatment Type

• Targeted Therapies
• Chemotherapy
• Surgery
• Other Treatments

By End-user

• Hospitals
• Specialty Clinics
• Home care
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In October 2022, Erasca, based extended its current collaboration with Pfizer to evaluate ERAS-007 when combined with Pfizer's Ibrance (palbociclib). Both biopharma will start clinical proof-of-concept research as part of the extended clinical trial collaboration and supply agreement. They will test their drug combination on patients with colorectal cancer who have mutations in the NRAS and KRAS genes as well as pancreatic ductal adenocarcinoma who have mutations in the KRAS gene.

Why Purchase the Report?

• To visualize the global pancreatic cancer market segmentation based on the type, therapy type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pancreatic cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global pancreatic cancer market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies